Two physician-led practices are making strong progress after recently launching their membership-based, preventive-care models in partnership with MDVIP.
Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from its Phase 2b clinical trial (LT3001-202) evaluating LT3001 (intravenous Odatroltide) in patients with acute ischemic stroke.
The council unites leading scientists, clinicians, and advocates to ensure that cutting-edge research and lived experience together shape the future of mental health care.
Le Bonheur Children’s Hospital and the University of Tennessee Health Science Center (UTHSC) are proud to announce the appointment of Jason S. Frischer, MD, as Surgeon-in-Chief and Chief of Pediatric Surgery.
The NCPDP Foundation is pleased to announce the successful completion of a study conducted by the University of Tennessee Health Science Center, College of Pharmacy.
